GLYBURIDE Drug Patent Profile

When do Glyburide patents expire, and when can generic versions of Glyburide launch?

Glyburide is a drug marketed by Actavis Elizabeth, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Epic Pharma Llc, Heritage, Impax Labs Inc, Orient Pharma Co Ltd, Teva, Zydus Pharms, Hikma, Natco Pharma, Sanofi Aventis Us, and Strides Pharma Intl. and is included in twenty-three NDAs.

The generic ingredient in GLYBURIDE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glyburide

A generic version of GLYBURIDE was approved as glyburide; metformin hydrochloride by IMPAX LABS INC on February 18^th, 2004.

Summary for GLYBURIDE

US Patents:	0
Applicants:	14
NDAs:	23

US Patents and Regulatory Information for GLYBURIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	GLYBURIDE (MICRONIZED)	glyburide	TABLET;ORAL	020055-003	Mar 8, 2000		DISCN	No	No
Chartwell Rx	GLYBURIDE (MICRONIZED)	glyburide	TABLET;ORAL	075174-002	Jun 22, 1998		DISCN	No	No
Teva	GLYBURIDE (MICRONIZED)	glyburide	TABLET;ORAL	074686-004	Apr 20, 1999		RX	No	Yes

Glyburide: Market Landscape and Patent Expirations

Last updated: February 19, 2026

Glyburide, an oral sulfonylurea antidiabetic medication, maintains a significant presence in the treatment of type 2 diabetes. Its efficacy, established therapeutic profile, and cost-effectiveness continue to support its market share, particularly in regions where generic availability is prevalent. The drug's patent landscape has largely expired, leading to widespread generic competition and influencing market dynamics.

What is Glyburide and How Does it Work?

Glyburide is a second-generation sulfonylurea medication used to manage type 2 diabetes mellitus. It functions by stimulating the pancreas to produce more insulin and by increasing the sensitivity of peripheral tissues to insulin, thereby lowering blood glucose levels.

• Mechanism of Action: Glyburide binds to the sulfonylurea receptor on pancreatic beta cells, leading to the closure of ATP-sensitive potassium channels. This closure depolarizes the beta cell membrane, triggering calcium influx and subsequent insulin granule exocytosis.
• Therapeutic Use: It is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
• Dosage Forms: Glyburide is available in immediate-release and micronized formulations, typically administered orally once or twice daily.

Glyburide's Market Position and Competition

The market for glyburide is characterized by mature product lifecycles and a high degree of generic penetration. Competition primarily stems from other oral antidiabetic agents, including other sulfonylureas, metformin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.

• Key Competitors:
  • Metformin: The first-line treatment for type 2 diabetes, often used in combination with other agents.
  • Other Sulfonylureas: Glipizide, glimepiride, and tolbutamide offer similar mechanisms of action but may differ in pharmacokinetic profiles and side effect profiles.
  • Newer Drug Classes: DPP-4 inhibitors (e.g., sitagliptin), SGLT2 inhibitors (e.g., empagliflozin), and GLP-1 receptor agonists (e.g., liraglutide) represent newer therapeutic options with distinct mechanisms and cardiovascular benefits, increasingly displacing older agents in certain patient populations.
• Market Drivers:
  • Cost-Effectiveness: Glyburide's established generic status makes it a highly affordable treatment option, a critical factor in many healthcare systems and for cost-conscious patients.
  • Established Efficacy: Decades of clinical use have validated its effectiveness in lowering HbA1c.
  • Broad Accessibility: Widely available in pharmacies globally.
• Market Restraints:
  • Side Effect Profile: Potential for hypoglycemia, weight gain, and gastrointestinal disturbances.
  • Cardiovascular Risk: Unlike some newer antidiabetics, glyburide does not offer primary or secondary cardiovascular benefits.
  • Limited Efficacy in Advanced Disease: May become less effective as beta-cell function declines.

Patent Landscape and Generic Entry

The original patents protecting glyburide have long since expired, opening the door for generic manufacturers. This has led to a significant reduction in the drug's price and has shifted the competitive landscape to one dominated by generic competition.

• Original Patent Expirations:
  • The primary compound patents for glyburide expired in the early to mid-1990s. For example, the key U.S. patent for glyburide, U.S. Patent No. 3,507,843, expired in 1992.
  • Subsequent patents related to specific formulations or manufacturing processes also expired, allowing for broad generic market entry.
• Impact of Generic Entry:
  • Price Erosion: Generic glyburide is available at a fraction of the cost of branded formulations, often less than $10 for a 30-day supply.
  • Market Share Domination: Generic versions account for over 95% of glyburide prescriptions in many markets.
  • Increased Accessibility: Lower prices have made the medication accessible to a wider patient base.
• Current Patent Status:
  • As of [current year], there are no active patents that would prevent the sale of generic glyburide. Any remaining patents are likely expired or related to niche, non-commercial aspects of the drug.

Regulatory Approvals and Manufacturing

Glyburide has received approval from major regulatory bodies worldwide, facilitating its global distribution. The manufacturing process is well-established, with numerous active pharmaceutical ingredient (API) and finished dosage form manufacturers in operation.

• Key Regulatory Approvals:
  • U.S. Food and Drug Administration (FDA): Approved for marketing as an antidiabetic agent.
  • European Medicines Agency (EMA): Approved in European Union member states.
  • Other National Authorities: Approved in Canada, Japan, Australia, and numerous other countries.
• Manufacturing Considerations:
  • API Sourcing: Glyburide API is manufactured by multiple companies globally, primarily in India and China, contributing to competitive pricing.
  • Finished Dosage Forms: Generic manufacturers in various regions produce tablets and capsules for local and international markets.
  • Quality Standards: Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure product quality and safety.

Investment and R&D Outlook

The investment and research and development (R&D) outlook for glyburide is limited due to its status as a mature, off-patent drug. Opportunities are primarily in the generic manufacturing and distribution space, rather than novel drug discovery or development.

• Investment Focus:
  • Generic Manufacturing: Companies with efficient API synthesis and tablet manufacturing capabilities can compete on cost.
  • Supply Chain Optimization: Ensuring a reliable and cost-effective supply chain for generic glyburide is crucial for market participants.
  • Emerging Markets: Glyburide remains a vital treatment option in developing economies due to its affordability.
• R&D Landscape:
  • No Significant Novel R&D: Innovation efforts have shifted to newer drug classes with improved efficacy and safety profiles.
  • Limited Formulation Development: While improved formulations (e.g., extended-release) have been developed in the past, these are also largely genericized.
  • Repurposing: There is minimal to no ongoing R&D for glyburide's repurposing in other therapeutic areas.
• Market Dynamics for Investors:
  • Price Pressure: Intense competition among generic manufacturers exerts continuous downward pressure on prices.
  • Volume-Driven Market: Profitability relies on high sales volumes rather than premium pricing.
  • Regulatory Hurdles: Navigating regulatory requirements for API and finished product approvals in different markets is essential.

Glyburide's Place in Evolving Diabetes Treatment Guidelines

Current diabetes treatment guidelines increasingly emphasize therapies that offer glycemic control, weight management, and cardiovascular/renal protection. This trend is impacting the role of older agents like glyburide.

• American Diabetes Association (ADA) Guidelines:
  • First-Line Therapy: Metformin remains the preferred initial oral agent.
  • Second-Line Therapy: Choice depends on patient comorbidities. Agents with proven cardiovascular and/or renal benefits (SGLT2 inhibitors, GLP-1 receptor agonists) are often recommended for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.
  • Sulfonylureas: Glyburide and other sulfonylureas are generally considered in patients for whom cost is a primary barrier or when other agents are contraindicated or not tolerated. They are not recommended for patients at high risk of hypoglycemia or those with significant renal impairment.
• European Society of Cardiology (ESC) Guidelines:
  • Similar to ADA, ESC guidelines prioritize agents with cardiorenal benefits for patients with established cardiovascular disease or high cardiovascular risk.
  • Sulfonylureas are typically positioned as older, less preferred options, primarily due to their hypoglycemia risk and lack of cardioprotective benefits.
• Impact on Glyburide Usage:
  • While still prescribed, especially in cost-sensitive markets or for specific patient profiles, glyburide's position as a preferred agent has diminished.
  • The advent of newer, more comprehensive therapies with demonstrated benefits in reducing cardiovascular events and slowing kidney disease progression means glyburide is less likely to be a first- or second-choice agent for many patients.

Challenges and Risks Associated with Glyburide

Despite its long history, glyburide presents specific challenges and risks for both patients and healthcare providers.

• Hypoglycemia: The most significant risk associated with sulfonylureas. Hypoglycemic episodes can range from mild to severe and life-threatening. The risk is higher in elderly patients, those with renal or hepatic impairment, and when combined with other medications that can lower glucose.
• Weight Gain: Sulfonylureas, including glyburide, can promote weight gain, which is counterproductive in the management of type 2 diabetes, a condition often linked to obesity.
• Renal and Hepatic Impairment: Glyburide is metabolized by the liver and excreted by the kidneys. Impairment in these organs can lead to drug accumulation and an increased risk of adverse effects, particularly hypoglycemia. Dose adjustments or avoidance may be necessary.
• Cardiovascular Safety Concerns: While not directly causing cardiovascular events, glyburide does not offer the protective benefits seen with newer diabetes medications. This makes it a less desirable option for patients with or at high risk for cardiovascular disease.
• Drug Interactions: Glyburide can interact with numerous medications, including other antidiabetics, beta-blockers, salicylates, and certain antibiotics, potentially increasing the risk of hypoglycemia or other adverse effects.

Future Market Projections for Glyburide

The market for glyburide is expected to remain stable in volume but likely experience continued price declines due to generic competition. Its primary role will likely be as an affordable option in specific patient populations and geographic regions.

• Projected Market Trends:
  • Volume Stability: Demand for glyburide is expected to persist, particularly in developing countries and for cost-constrained healthcare systems.
  • Price Decline Continuation: Ongoing price erosion due to generic competition will continue.
  • Declining Market Share in Developed Nations: In countries with widespread access to newer antidiabetic agents, glyburide's market share will likely continue to shrink gradually.
  • Niche Treatment Role: It will remain a viable option for patients who cannot tolerate or afford newer therapies, provided they are carefully monitored for hypoglycemia.
• Key Influencing Factors:
  • Healthcare Policy: Government policies on drug pricing and formulary inclusions will play a significant role.
  • Availability of Generics: The number of generic manufacturers and their pricing strategies will impact market dynamics.
  • Evolution of Diabetes Treatment: Future guidelines and the introduction of even more effective therapies could further reduce glyburide's utility.

Key Takeaways

Glyburide, an established oral antidiabetic, has a mature market characterized by widespread generic availability following patent expirations in the early to mid-1990s. Its cost-effectiveness and proven efficacy in lowering blood glucose continue to support its use, particularly in emerging markets and for price-sensitive patient populations. However, newer antidiabetic drug classes offer superior benefits, including cardiovascular and renal protection, and are increasingly favored in updated treatment guidelines, leading to a diminished role for glyburide in developed healthcare systems. Investment opportunities lie primarily in efficient generic manufacturing and supply chain management, with limited prospects for novel R&D. The primary risks associated with glyburide are hypoglycemia, weight gain, and a lack of cardiovascular benefits, necessitating careful patient selection and monitoring.

Frequently Asked Questions

1. When did the primary patents for glyburide expire? The primary compound patents for glyburide expired in the early to mid-1990s, with U.S. Patent No. 3,507,843 expiring in 1992.

2. What are the main therapeutic advantages of glyburide compared to newer antidiabetic drugs? The primary advantage of glyburide is its cost-effectiveness due to its status as a long-established generic medication, making it accessible to a broader patient base.

3. What is the most significant safety concern associated with glyburide treatment? The most significant safety concern is the risk of hypoglycemia, which can be severe and requires careful patient monitoring.

4. How do current diabetes treatment guidelines position glyburide relative to newer medications? Current guidelines generally position glyburide as a less preferred option compared to newer antidiabetic agents that offer additional benefits like cardiovascular and renal protection, reserving it for patients where cost is a primary barrier or other agents are not suitable.

5. Are there any ongoing research and development efforts for novel applications of glyburide? No, there are no significant ongoing research and development efforts focused on novel applications or repurposing of glyburide; innovation has shifted to newer drug classes.

Citations

[1] U.S. Patent No. 3,507,843. (1970). Sulfonylurea derivatives and process for their preparation. [2] American Diabetes Association. (2023). Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement_1). [3] Davies, M. J., Gagliardino, S. M., Barroso, S., & Signorovska, A. (2018). Type 2 diabetes mellitus in Europe: an economic perspective. Diabetologia, 61(7), 1444-1453. [4] Diabetes UK. (n.d.). All about diabetes. Retrieved from https://www.diabetes.org.uk/guide-to-diabetes/what-is-diabetes/types-of-diabetes